Intranasal corticosteroids (INS) (corticosteroid nasal sprays) and oral antihistamines (OA) are two of the most common treatments for patients with allergic rhinitis (AR). To our knowledge, there are no systematic reviews on this topic including trials published after 2007.
Objective
To compare INS with nonsedating OAs as treatments for AR.
Methods
The systematic review and meta-analysis were based on the Grades of Recommendation, Assessment, Development, and Evaluation principles and the Patient, Intervention, Comparison, and Outcome approach. Primary literature was searched up to January 22, 2015. Criteria for eligibility were randomized controlled trials that compared the efficacy and/or adverse effects of INS and OA in patients with AR. Continuous outcome data were analyzed by using standardized mean differences (SMD) for multiple outcome measures, and mean differences in the case of a single study or outcome. Pooled estimates of effects, 95% confidence interval (CI), were calculated by using random-effects models.
Results
The meta-analysis included five randomized controlled trials with a total of 990 patients. INS were superior to OAs in improving total nasal symptoms score (SMD -0.70 [95% CI, -0.93 to -0.477]) and in relieving the following: nasal obstruction (SMD -0.56 [95% CI, -0.82 to -0.29]), rhinorrhea (SMD -0.47 [95% CI, -1.00 to 0.05]), nasal itching (SMD -0.42 [95% CI, -0.65 to -0.18]), sneezing (SMD -0.52 [95% CI, -0.73 to -0.32]), and quality of life mean difference -0.90 [95% CI, -1.18 to -0.62]). There was no difference in relief of ocular symptoms (SMD -0.08 [95% CI, -0.23 to 0.08]). In addition, four randomized controlled trials were included in a narrative analysis. The results in the narrative analysis were comparable with those found in the meta-analysis.
Conclusion
INS were superior to OAs in improving nasal symptoms and quality of life in patients with AR.
Get full access to this article
View all access options for this article.
References
1.
LinnebergA., NielsenN.H., MadsenF.Increasing prevalence of specific IgE to aeroallergens in an adult population: Two cross-sectional surveys 8 years apart: The Copenhagen Allergy Study.J Allergy Clin Immunol106: 247–252, 2000.
2.
WarmK., LindbergA., LundbackB., and RonmarkE.Increase in sensitization to common airborne allergens among adults—Two population-based studies 15 years apart.Allergy Asthma Clin Immunol9: 20, 2013.
3.
BauchauV., and DurhamS.R.Prevalence and rate of diagnosis of allergic rhinitis in Europe.Eur Respir J24: 758–764, 2004.
4.
NathanR.A., MeltzerE.O., DereberyJ.The prevalence of nasal symptoms attributed to allergies in the United States: Findings from the burden of rhinitis in an America survey.Allergy Asthma Proc29: 600–608, 2008.
5.
MeltzerE.O., GrossG.N., KatialR., and StormsW.W.Allergic rhinitis substantially impacts patient quality of life: Findings from the Nasal Allergy Survey Assessing Limitations.J Fam Pract61(suppl.): S5–S10, 2012.
6.
HoyteF.C., MeltzerE.O., OstromN.K.Recommendations for the pharmacologic management of allergic rhinitis.Allergy Asthma Proc35(suppl 1): S20–S27, 2014.
7.
BergerW., BousquetJ., FoxA.T.MP-AzeFlu is more effective than fluticasone propionate for the treatment of allergic rhinitis in children.Allergy71: 1219–1222, 2016.
8.
KalpakliogluA.F., and KavutA.B.Comparison of azelastine versus triamcinolone nasal spray in allergic and nonallergic rhinitis.Am J Rhinol Allergy24: 29–33, 2010.
9.
GuyattG., OxmanA.D., AklE.A.GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables.J Clin Epidemiol64: 383–394, 2011.
10.
RichardsonW.S., WilsonM.C., NishikawaJ., and HaywardR.S.The well-built clinical question: A key to evidence-based decisions.ACP J Club123: A12–A13, 1995.
11.
BalshemH., HelfandM., SchunemannH.J.GRADE guidelines: 3. Rating the quality of evidence.J Clin Epidemiol64: 401–406, 2011.
GuyattG.H., OxmanA.D., VistG.GRADE guidelines: 4. Rating the quality of evidence—Study limitations (risk of bias).J Clin Epidemiol64: 407–415, 2011.
16.
GuyattG.H., OxmanA.D., KunzR.GRADE guidelines: 7. Rating the quality of evidence—Inconsistency.J Clin Epidemiol64: 1294–1302, 2011.
17.
GuyattG.H., OxmanA.D., KunzR.GRADE guidelines: 8. Rating the quality of evidence—Indirectness.J Clin Epidemiol64: 1303–1310, 2011.
18.
GuyattG.H., OxmanA.D., KunzR.GRADE guidelines 6. Rating the quality of evidence—Imprecision.J Clin Epidemiol64: 1283–1293, 2011.
19.
GuyattG.H., OxmanA.D., MontoriV.GRADE guidelines: 5. Rating the quality of evidence—Publication bias.J Clin Epidemiol64: 1277–1282, 2011.
20.
GRADEpro Guideline Development Tool [Software], McMaster University, 2015, developed by Evidence Prime, Inc., available from gradepro.org. Accessed January 11, 2015.
21.
BrozekJ.L., BousquetJ., Baena-CagnaniC.E.Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision.J Allergy Clin Immunol126: 466–476, 2010.
22.
D'AmbrosioF.P., GangemiS., MerendinoR.A.Comparative study between fluticasone propionate and cetirizine in the treatment of allergic rhinitis.Allergol Immunopathol (Madr)26: 277–282, 1998.
23.
FokkensW.J., and ScaddingG.K.Perennial rhinitis in the under 4s: A difficult problem to treat safely and effectively? A comparison of intranasal fluticasone propionate and ketotifen in the treatment of 2-4-year-old children with perennial rhinitis.Pediatr Allergy Immunol15: 261–266, 2004.
24.
MunchE.P., SoborgM., NorresletT.T., and MygindN.A comparative-study of dexchlorpheniramine maleate sustained-release tablets and budesonide nasal spray in seasonal allergic rhinitis.Allergy38: 517–524, 1983.
25.
RinneJ., SimolaM., MalmbergH., and HaahtelaT.Early treatment of perennial rhinitis with budesonide or cetirizine and its effect on long-term outcome.J Allergy Clin Immunol109: 426–432, 2002.
26.
TakahashiG., MatsuzakiZ., OkamotoA.A randomized control trial of stepwise treatment with fluticasone propionate nasal spray and fexofenadine hydrochloride tablet for seasonal allergic rhinitis.Allergol Int61: 155–162, 2012.
27.
KulapaditharomB., PornprasertsukK., and BoonkitticharoenV.Clinical assessment of levocetirizine and budesonide in treatment of persistent allergic rhinitis regarding to symptom severity.J Med Assoc Thai93: 215–223, 2010.
28.
BenderB.G., and MilgromH.Comparison of the effects of fluticasone propionate aqueous nasal spray and loratadine on daytime alertness and performance in children with seasonal allergic rhinitis.Ann Allerg Asthma Immunol92: 344–349, 2004.
29.
CondemiJ., SchulzR., and LimJ.Triamcinolone acetonide aqueous nasal spray versus loratadine in seasonal allergic rhinitis: Efficacy and quality of life.Ann Allergy Asthma Immunol84: 533–538, 2000.
30.
RatnerP.H., van BavelJ.H., MartinB.G.A comparison of the efficacy of fluticasone propionate aqueous nasal spray and loratadine, alone and in combination, for the treatment of seasonal allergic rhinitis.J Fam Pract47: 118–125, 1998.
31.
GehannoP., and DesfougeresJ.L.Fluticasone propionate aqueous nasal spray compared with oral loratadine in patients with seasonal allergic rhinitis.Allergy52: 445–450, 1997.
32.
KaszubaS.M., BaroodyF.M., deTineoM.Superiority of an intranasal corticosteroid compared with an oral antihistamine in the as-needed treatment of seasonal allergic rhinitis.Arch Intern Med161: 2581–2587, 2001.
33.
SchoenwetterW., and LimJ.Comparison of intranasal triamcinolone acetonide with oral loratadine for the treatment of patients with seasonal allergic rhinitis.Clin Ther17: 479–492, 1995.
34.
JordanaG., DolovichJ., BriscoeM.P.Intranasal fluticasone propionate versus loratadine in the treatment of adolescent patients with seasonal allergic rhinitis.J Allergy Clin Immunol97: 588–595, 1996.
MinY.G.The pathophysiology, diagnosis and treatment of allergic rhinitis.Allergy Asthma Immunol Res2: 65–76, 2010.
37.
Koca KalkanI., Baccioglu KavutA., KalpakliogluA.F.Allergic rhinitis: Can we identify nonadherence to therapy and its predictors easily in daily practice?J Investig Allergol Clin Immunol23: 315–322, 2013.
38.
CervinA., and AnderssonM.Intranasal steroids and septum perforation—An overlooked complication? A description of the course of events and a discussion of the causes.Rhinology36: 128–132, 1998.
39.
SchackeH., DockeW.D., and AsadullahK.Mechanisms involved in the side effects of glucocorticoids.Pharmacol Ther96: 23–43, 2002.
40.
SchenkelE.J., SkonerD.P., BronskyE.A.Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray.Pediatrics105: E22, 2000.
41.
AllenD.B., MeltzerE.O., LemanskeR.F.Jr.No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year.Allergy Asthma Proc23: 407–413, 2002.
42.
MurphyK., UryniakT., SimpsonB., and O'DowdL.Growth velocity in children with perennial allergic rhinitis treated with budesonide aqueous nasal spray.Ann Allergy Asthma Immunol96: 723–730, 2006.
43.
SkonerD.P., BergerW.E., GawchikS.M.Intranasal triamcinolone and growth velocity.Pediatrics135: e348–e356, 2015.
44.
RobertsG., XatzipsaltiM., BorregoL.M.Paediatric rhinitis: Position paper of the European Academy of Allergy Clinical Immunology.Allergy68: 1102–1116, 2013.
45.
FordL.B., MatzJ., HankinsonT.A comparison of fluticasone propionate nasal spray and cetirizine in ragweed fall seasonal allergic rhinitis.Allergy Asthma Proc36: 313–319, 2015.
